For Healthcare Professionals / Registered Medical Practitioners Only Login | Register

Blog on Fluid-Overload is out for the month of July 
Vulnerable Patients Risk of CLABSI

FLEXBUMIN®
IN DAILY

PRACTICE

Description

SOME PATIENTS 
IN NEED OF 
ALBUMIN THERAPY

May be at an increased risk of 
developing CLABSI
due to their underlying disease or condition.1

ASCITES

An increased risk of CLABSI rates have been observed in immuno-compromised patients.1

Description
Description

POST SURGERY

Underlying diseases such as gastrointestinal diseases have been associated with an increased risk of CLABSI.1

TRAUMA & BURN

Patients in trauma critical care and burn units suffer from the highest CLABSI rates.1

Description

REFERENCES

  1. The Joint Commission. Preventing Central Line-Associated Bloodstream Infections: A Global Challenge, A Global Perspective. Oak Brook, IL: Joint Commission Resources; May 2012. Accessed November 2020. https://www.jointcommission.org/-/media/deprecated-unorganized/imported-assets/tic/system-folders/topics-library/clabsi_monographpdf.pdf?db=web&hash=86103821F3C7FF8A7683C933EA0CB391
  2. Four-layer bag technology - Ref-35896- Baxter - May 2017.
  3. Maki DG, et al. Impact of Switching from an Open to a Closed Infusion System on Rates of Central Line-Associated Bloodstream Infection: A Meta-analysis of Time-Sequence Cohort Studies in 4 Countries. Infect Control Hosp Epidemiol. 2011;32:50-58.
  4. Flexbumin® India Prescribing Information (PI).
  5. Jarvis WR, et al. INICC Care Bundles to Prevent Central and Peripheral Line-Related Bloodstream Infections. International Nosocomial Infection Control Consortium. 2017:1-49. Accessed November 2020. http://www.inicc.org/media/docs/2017-INICCBSIPreventionGuidelines.pdf
  6. O'Grady NP, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011. Updated 2017. Accessed November 2020. https://www.cdc.gov/infectioncontrol/quidelines/bsi/index.html
  7. Orsi GB, et al. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs. Infect Control Hosp Epidemiol 2002:23(4):190-197.
  8. Summary Report of Observations for Flexbumin bags and Buminate bottles. Shire, Data on File. ID: FLEX-005. July 2017.
  9. Viaflo Key Features User Guide - June 2014.

Therapeutic Indication: Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is approprite.
The choice of albumin rather then artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.

This website is intended to provide information to Healthcare Professionals and/or Registered Medical Practitioners only; it should not be used for diagnosing or treating a health problem or disease. Healthcare professionals and registered medical practitioners shall apply their independent medical judgment and patient analysis for assessing any patient and not rely on the material provided on this Website. It contains information on FLEXBUMIN®, which is based on the India Prescribing Information (PI). This website has been developed by Takeda in accordance with industry and legal standards about FLEXBUMIN®. Takeda makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive. This website is not intended to be used to report adverse events or product quality complaints. If you would like to report an adverse event or product quality complaint, please contact us at AE.India@takeda.com.

This information is solely intended for the use of Registered Medical Practitioner and Hospital only. This information should not be used or shared or distributed to any other person/party and should be strictly by the intended parties for the intended purposes only.For more information please refer to full Prescribing Information

This material contains copyright protected information, content; the use of which is limited by law and this material cannot be reproduced,replicated, used or modified by any person for their own use or further distribution.

FLEXBUMIN® is trademark or registered trademark of Baxalta Incorporated. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited.

C-APROM/IN/FLEX/0286
Preparation Date: 27/May/2025

Takeda
Copyright ©2025 Takeda Pharmaceutical Company Limited. All rights reserved.

Privacy Policy

Terms of Use

Prescribing Information

Safety Information

Contact